Join the Burosumab group to help and get support from people like you.
Burosumab News
Ultragenyx and Kyowa Kirin Announce U.S. FDA Approval of Crysvita (burosumab) for the Treatment of Tumor-Induced Osteomalacia (TIO)
NOVATO, Calif. and TOKYO, June 18, 2020 (GLOBE NEWSWIRE) – Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel...
FDA Approves Label Update for Crysvita (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH) in Pediatric Patients 6 Months of Age and Older
NOVATO, Calif., and TOKYO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare a...
FDA Approves Crysvita (burosumab-twza) for X-Linked Hypophosphatemia
April 17, 2018 – The U.S. Food and Drug Administration today approved Crysvita (burosumab), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia...
Ask a question
To post your own question to this support group, sign in or create an account.